Drug intelligence / Profile preview

NNC16790001

Development stage: Phase 1
Lead developer: Novo Nordisk
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

NNC16790001 (also known as NNC1679-0001) is an investigational small interfering RNA (siRNA) therapeutic being developed by Novo Nordisk for the treatment of type 2 diabetes mellitus. The drug is designed to selectively silence a specific, undisclosed target gene involved in metabolic regulation using RNA interference (RNAi) technology, which was acquired through Novo Nordisk's acquisition of Dicerna Pharmaceuticals and its GalXC platform. NNC16790001 is administered subcutaneously and is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants and individuals with type 2 diabetes.

Targets

AGO2 (Argonaute RISC catalytic component 2)ASGPR (Asialoglycoprotein Receptor 1)DICER1 (Dicer ribonuclease III)

Beyond the preview

Go deeper on NNC16790001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC16790001.

Explore the full profile